Grimes & Company, Inc. Akebia Therapeutics, Inc. Transaction History
Grimes & Company, Inc.
- $3.22 Billion
- Q1 2024
A detailed history of Grimes & Company, Inc. transactions in Akebia Therapeutics, Inc. stock. As of the latest transaction made, Grimes & Company, Inc. holds 10,000 shares of AKBA stock, worth $9,500. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,000Holding current value
$9,500% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding AKBA
# of Institutions
127Shares Held
56.7MCall Options Held
937KPut Options Held
743K-
Satter Management Co., L.P.13.2MShares$12.5 Million26.98% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.23MShares$7.81 Million0.0% of portfolio
-
Acadian Asset Management LLC Boston, MA5.31MShares$5.04 Million0.03% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny3.65MShares$3.47 Million0.01% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny3.27MShares$3.1 Million0.0% of portfolio
About Akebia Therapeutics, Inc.
- Ticker AKBA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 183,848,992
- Market Cap $175M
- Description
- Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...